Eosinophilic Esophagitis Treatment Market 2022-2028

Description

List of Tables

Global Eosinophilic Esophagitis Treatment Market Size, Share & Trends Analysis Report By Product (Budesonide Oral Suspension, Fluticasone ODT, Mepolizumab, Reslizumab, Benralizumab, and Others), By Diagnosis (Upper Endoscopy, Esophagus Biopsy, and Blood Tests), and By Treatment (Dietary Therapy, Medication, and Dilation) Forecast, 2022-2028

The global eosinophilic esophagitis treatment market is anticipated to grow at a substantial CAGR of 6.4% during the forecast period. The market is set to display impressive growth during the forecast period with some key trends emerging, such as the increased reimbursement scenario in eosinophilic esophagitis along with the growing usage of proton pump inhibitors across the globe. Additionally, increasing awareness programs for eosinophil-associated disorders is also estimated to be the prime factor affecting and impacting the growth of the market.

The global eosinophilic esophagitis treatment market had been positively affected during the COVID-19 pandemic as most of the economic activities were halted during Q1 and Q2 2020. The temporary shutdown of every manufacturing unit had adversely impacted, the growth of the market. However, a various initiative taken by government across the globe is improving market growth.

The global eosinophilic esophagitis treatment market is segmented based on product, diagnosis, and treatment. By product, the market is segmented into budesonide oral suspension, fluticasone ODT, mepolizumab, reslizumab, benralizumab, and others. Further, based on the diagnosis segment, the market is segmented into upper endoscopy, esophagus biopsy, and blood tests. Based on the treatment segment, the market is divided into dietary therapy, medication, and dilation.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific is having a significant share in the market for eosinophilic esophagitis treatment. Improving and increasing awareness regarding eosinophilic esophagitis which was once a stronghold of the US and a few European economies such as France, Italy, and Germany is set to expand in emerging economies. The increasing healthcare developments among the population in the Asian economies of Japan, South Korea, Taiwan, and China, which involve the highest degree of innovations, is set to increase the demand for the eosinophilic esophagitis treatment market.

The prominent players functioning in the global eosinophilic esophagitis treatment market include AstraZeneca, Bristol-Myers Squibb, Dr Falk Pharma, Novartis AG, Regeneron Pharmaceuticals, Inc., and Teva Pharmaceuticals Industries Ltd. among others. These key manufacturers are adopting various strategies such as new product launches and approvals, mergers and acquisitions, partnerships, and collaborations, and many others to thrive in a competitive environment. For instance, in October 2018, one of the companies named Dr Falk Pharma had introduced across the UK its Jorveza which is considered as the first globally licensed drug approved for eosinophilic esophagitis.

Research Methodology

The market study of the global eosinophilic esophagitis treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.
Whitepapers, research papers, and news blogs.
Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Eosinophilic Esophagitis Treatment Market Research And Analysis By Product

2. Global Eosinophilic Esophagitis Treatment Market Research And Analysis By Diagnosis

3. Global Eosinophilic Esophagitis Treatment Market Research And Analysis By Treatment

The Report Covers:

Comprehensive Research Methodology of the global eosinophilic esophagitis treatment market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global eosinophilic esophagitis treatment market.
Insights about market determinants that are stimulating the global eosinophilic esophagitis treatment market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2026287

1. Report Summary

1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Geography

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
- 3.1.1. Overview
- 3.1.2. Financial Analysis
- 3.1.3. SWOT Analysis
- 3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players

4. Market Segmentation

4.1. Global Eosinophilic Esophagitis Treatment Market by Product
- 4.1.1. Budesonide Oral Suspension
- 4.1.2. Fluticasone ODT
- 4.1.3. Mepolizumab
- 4.1.4. Reslizumab
- 4.1.5. Benralizumab
- 4.1.6. Others
4.2. Global Eosinophilic Esophagitis Treatment Market by Diagnosis
- 4.2.1. Upper Endoscopy
- 4.2.2. Esophagus Biopsy
- 4.2.3. Blood Tests
4.3. Global Eosinophilic Esophagitis Treatment Market by Treatment
- 4.3.1. Dietary Therapy
- 4.3.2. Medication
- 4.3.3. Dilation

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Adare Pharmaceuticals, Inc.
6.2. Allakos, Inc.
6.3. Astrazeneca
6.4. Axcan Pharma, Inc.
6.5. Bristol-Myers Squibb
6.6. Celgene Corp.
6.7. Ception Therapeutics Inc.
6.8. Dr. Falk Pharma Gmbh
6.9. DBV Technologies
6.10. Hikma Pharmaceuticals Plc
6.11. Novartis AG
6.12. Perrigo Co. Plc
6.13. Regeneron Pharmaceuticals, Inc.
6.14. Sun Pharmaceutical Industries Ltd.
6.15. Teva Pharmaceuticals Industries Ltd.